薛世民; 蒋伟; 贾娟; 张王锋; 吴桂莲
June 2016
Progress in Modern Biomedicine;Jun2016, Vol. 16 Issue 18, p3551
Academic Journal
Objective: To investigate the clinical efficacy of moxifloxacin in the treatment of elderly patients with mycoplasma pneumonia. Methods: 80 elderly patients with mycoplasma pneumonia who were admitted in our hospital were randomly divided into the control group and the experimental group, with 40 cases in each group, and all the patients were treated with the conventional symptomatic methods. Besides, the control group was treated with erythromycin, while the experimental group was given moxifloxacin.At the end of treatment, the fever, hospitalization time, WBC count, CRP levels and clinical total efficiency Were compared between two groups. Results: Compared with before treatment, the WBC counts and CRP levels of both groups after treatment were significantly decreased(P<0.05), and the antipyretic time and hospitalization time of experimental group were significantly shorter than those of the control group(P<0.05), and the WBC count and CRP levels were significantly lower than the control group(P<0.05), while the clinical efficacy was significantly higher than that of the control group(P<0.05). Conclusion: Moxifloxacin could significantly improve the clinical efficacy of elderly patients with mycoplasma pneumonia.


Related Articles

  • Efficacy and Tolerability of Sequential Intravenous/Oral Moxifloxacin Therapy in Pneumonia: Results of the First Post-Marketing Surveillance Study with Intravenous Moxifloxacin in Hospital Practice. Barth, J.; Stauch, K.; Landen, H. // Clinical Drug Investigation;2005, Vol. 25 Issue 11, p691 

    Objective: This study aimed to investigate the efficacy, safety and tolerability of sequential intravenous (IV)/oral therapy with moxifloxacin in pneumonia under general hospital treatment conditions. Patients and methods: Patients with pneumonia were documented in this non-interventional...

  • Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. Benjamin A. Lipsky; Philip Giordano; Shurjeel Choudhri; James Song // Journal of Antimicrobial Chemotherapy (JAC);Aug2007, Vol. 60 Issue 2, p370 

    Objectives Complicated skin and skin structure infections (cSSSIs), including diabetic foot infections (DFIs), are often polymicrobial, requiring combination or broad-spectrum therapy. Moxifloxacin, a broad-spectrum fluoroquinolone, is approved for cSSSI and can be administered by either...

  • MOXIFLOXACIN: a once-daily, fourth-generation fluoroquinolone antibiotic Product Profile.  // Formulary;Jun2002 Supplement 3, Vol. 37 Issue 6, p9 

    Focuses on moxifloxacin, a fourth-generation fluorinated quinolone. Chemistry and mechanism of action; Antimicrobial activity; Clinical and microbial efficacy.

  • MOXIFLOXACIN: a once daily, fourth-generation fluoroquinolone antibiotic.  // Managed Healthcare Executive;Jun2002 Supplement 1, Vol. 12 Issue 6, p9 

    Analyzes the properties and clinical capabilities of moxifloxacin, the fourth-generation fluoroquinolone antibiotic. Availability of the drug in oral and intravenous formulations; Benefits of moxifloxacin; Bacteriological efficacy in treating acute bacterial exacerbation of chronic bronchitis.

  • Moxifloxacin is not anti-inflammatory in experimental pneumococcal pneumonia. Müller-Redetzky, H. C.; Wienhold, S. M.; Berg, J.; Hocke, A. C.; Hippenstiel, S.; Hellwig, K.; Gutbier, B.; Opitz, B.; Neudecker, J.; Rückert, J.; Gruber, A. D.; Kershaw, O.; Mayer, K.; Suttorp, N.; Witzenrath, M. // Journal of Antimicrobial Chemotherapy (JAC);Mar2015, Vol. 70 Issue 3, p830 

    Objectives Anti-inflammatory functions of antibiotics may counteract deleterious hyperinflammation in pneumonia. Moxifloxacin reportedly exhibits immunomodulatory properties, but experimental evidence in pneumonia is lacking. Therefore, we investigated moxifloxacin in comparison with ampicillin...

  • Moxifloxacin Monotherapy in Complicated Intra-abdominal Infections.  // Clinical Infectious Diseases;2/1/2007, Vol. 44 Issue 3, pv 

    The article presents the findings of the study that investigates the efficacy of moxifloxacin in the treatment of intra-abdominal infections. Hospital patients with intra-abdominal infection were treated with moxifloxacin or piperacillin in addition to surgical intervention. Findings revealed...

  • Efficacy and safety of moxifloxacin injection in treatment of acute exacerbation of chronic bronchitis. Tiantuo Zhang; Ping Chen; Chengshui Chen; Jiulong Kuang; Changzheng Wang; Xixin Yan; Xiaohong Yang; Yuxia Shao; Xiaochun Yang // Community Acquired Infection;Jul-Sep2015, Vol. 2 Issue 3, p93 

    Objective: To evaluate the clinical efficacy and safety of moxifloxacin injection in the treatment of acute exacerbation of chronic bronchitis (AECB) in daily clinical practice. Patients and Methods: From May 2009 to March 2011, a total of 1026 cases with AECB were collected from 43 hospitals in...

  • Differences Between Fourth-generation Fluoroquinolones. Olson, Randall J. // Ophthalmology Times;6/15/2005, Vol. 30 Issue 12, Special Section p9 

    Focuses on the differences among the fourth-generation fluoroquinolones, gatifloxacin and moxifloxacin, which have become the preferred agents for the prophylaxis and treatment of ocular infections. Identification of ocular penetration as an important aspect of an antibiotic's efficacy;...

  • Avelox OK'd to treat drug-resistant S. pneumoniae.  // Drug Topics;3/17/2003, Vol. 147 Issue 6, p10 

    Reports on the U.S. Food and Drug Administration's (FDA) approval of moxifloxacin or Avelox tablets/IV as therapy for community-acquired pneumonia (CAP) due to penicillin-resistant S. pneumoniae. Clinical and bacteriological efficacy of moxifloxacin in the treatment of S. pneumoniae.

  • Effects of Iron Supplements on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Humans. Stass, H.; Kubitza, D. // Clinical Pharmacokinetics;2001 Supplement 1, Vol. 40 Issue 1, p57 

    Objective: To investigate the effect of concomitant iron administration on the pharmacokinetics and tolerability of moxifloxacin. Design: This was a single-centre, nonblinded, randomised, 2-way crossover study in healthy male volunteers. Participants: 12 healthy males (age 19 to 41 years) were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics